研究者業績

Inage Terunaga

Inage Terunaga  (Terunaga Inage)

基本情報

所属
千葉大学 医学部附属病院 助教
学位
医学博士(2017年3月 千葉大学)

連絡先
terunaga.inagechiba-u.jp
研究者番号
40706909
J-GLOBAL ID
202201001765728174
researchmap会員ID
R000039788

外部リンク

学歴

 2

論文

 79
  • Masato Aragaki, Terunaga Inage, Mitsuaki Kawashima, Daisuke Taniguchi, Tatsuya Kato, Kazuhiro Yasufuku, Shaf Keshavjee, Marcelo Cypel
    JTCVS Techniques 26 159-162 2024年8月  
  • Takahiro Yamanaka, Yuichi Sakairi, Yuki Sata, Takahide Toyoda, Terunaga Inage, Kazuhisa Tanaka, Hidemi Suzuki, Yukiko Matsui, Ichiro Yoshino
    Journal of thoracic disease 16(2) 989-996 2024年2月29日  
    BACKGROUND: Home oxygen therapy (HOT) is used to treat chronic respiratory diseases and is sometimes required in patients with lung cancer after radical surgery. We aimed to identify the risk factors for postoperative home-based oxygen therapy in patients with lung cancer. METHODS: Patients who underwent surgery for primary lung cancer at Chiba University Hospital between January 2019 and March 2021 were included. Patients who did not undergo complete resection, died in hospital after surgery, or used oxygen therapy preoperatively were excluded. Eligible patients were divided into HOT and non-HOT groups. They were retrospectively analyzed for risk factors for postoperative HOT using medical records in a multivariate analysis. RESULTS: A total of 410 patients were included in this study, 24 (5.9%) of whom required HOT after surgery. The HOT group comprised significantly more men, heavy smokers, and patients with pulmonary comorbidities, low percent forced expiratory volume, percent forced vital capacity, predicted postoperative forced expiratory volume in 1 s, and postoperative pulmonary complications on univariate analysis. In a multivariate analysis, independent risk factors for postoperative HOT were pulmonary comorbidities [odds ratio (OR): 5.94; 95% confidence interval (CI): 1.64-21.5; P=0.002) and postoperative pulmonary complications (OR: 5.39; 95% CI: 2.14-13.5; P<0.001). The postoperative HOT application rate was calculated according to a formula developed for this purpose. CONCLUSIONS: Comorbid pulmonary diseases and postoperative pulmonary complications were significantly associated with postoperative HOT in patients with lung cancer.
  • Takahiro Ochi, Yuichi Sakairi, Jotaro Yusa, Yuki Sata, Takahide Toyoda, Terunaga Inage, Kazuhisa Tanaka, Hidemi Suzuki, Joji Ota, Takayuki Kondo, Naoya Kato, Ichiro Yoshino
    JTCVS techniques 23 158-160 2024年2月  
  • Yuki Sata, Masato Aragaki, Terunaga Inage, Nicholas Bernards, Alexander Gregor, Shinsuke Kitazawa, Fumi Yokote, Takamasa Koga, Hiroyuki Ogawa, Yoshihisa Hiraishi, Tsukasa Ishiwata, Andrew Effat, Kate Kazlovich, Harley Chan, Ichiro Yoshino, Kazuhiro Yasufuku
    JTCVS techniques 22 292-304 2023年12月  
    OBJECTIVE: Endobronchial ultrasound-guided transbronchial needle injection (EBUS-TBNI) may effectively treat acute pulmonary embolisms (PEs). Here, we assessed the effectiveness of clot dissolution and safety of tissue plasminogen activator (t-PA) injection using EBUS-TBNI in a 1-week survival study of a porcine PE model. METHODS: Six pigs with bilateral PEs were used: 3 for t-PA injection using EBUS-TBNI (TBNI group) and 3 for systemic administration of t-PA (systemic group). Once bilateral PEs were created, each 25 mg of t-PA injection using EBUS-TBNI for bilateral PEs (a total of 50 mg t-PA) and 100 mg of t-PA systemic administration was performed on day 1. Hemodynamic parameters, blood tests, and contrast-enhanced computed tomography scans were carried out at several time points. On day 7, pigs were humanely killed to evaluate the residual clot volume in the pulmonary arteries. RESULTS: The average of percent change of residual clot volumes was significantly lower in the TBNI group than in the systemic group (%: systemic group 36.6 ± 22.6 vs TBNI group 9.6 ± 6.1, P < .01) on day 3. Considering the elapsed time, the average decrease of clot volume per hour at pre-t-PA to post t-PA was significantly greater in the TBNI group than in the systemic group (mm3/hour: systemic 68.1 ± 68.1 vs TBNI 256.8 ± 148.1, P < .05). No hemorrhage was observed intracranially, intrathoracically, or intraperitoneally on any contrast-enhanced computed tomography images. CONCLUSIONS: This study revealed that t-PA injection using EBUS-TBNI is an effective and safe way to dissolve clots.
  • Ryo Karita, Hidemi Suzuki, Yuki Onozato, Taisuke Kaiho, Terunaga Inage, Takamasa Ito, Kazuhisa Tanaka, Yuichi Sakairi, Ichiro Yoshino
    Surgery today 2023年10月25日  

MISC

 344

共同研究・競争的資金等の研究課題

 1